The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer’s Disease

Rujeedawa, Tanzil; Félez, Eva Carrillo; Clare, Isabel C. H.; Fortea, Juan; Strydom, André; Rebillat, Anne-Sophie; Coppus, Antonia; Levin, Johannes; Zaman, Shahid

doi:10.3390/jcm10194582

Cited by 18 publications

(10 citation statements)

References 252 publications

(345 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is likely that persons in the AD cohort did not have specific symptoms related to AD in the beginning of the assessment period. The early symptoms may pass unrecognized [ 20 ], and there might be a variety of unspecific symptoms including e.g. musculoskeletal disorders such as abnormal posture and unsteady gait, and neurological and psychological symptoms such as executive dysfunction and neuropsychiatric symptoms, which may occur before noticeable cognitive decline [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…The early symptoms may pass unrecognized [ 20 ], and there might be a variety of unspecific symptoms including e.g. musculoskeletal disorders such as abnormal posture and unsteady gait, and neurological and psychological symptoms such as executive dysfunction and neuropsychiatric symptoms, which may occur before noticeable cognitive decline [ 20 ]. Therefore, as the stays/visits start to increase at the AD cohort already at the beginning of the assessment period, it is likely that these are due to these unspecific symptoms but also other comorbidities related to AD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic groups of hospital stays and outpatient visits during 10 years before Alzheimer’s disease

Mäklin

Lampela

Lin

et al. 2023

BMC Health Serv Res

View full text Add to dashboard Cite

Background Alzheimer’s disease (AD) is a major determinant of healthcare costs and increase in the healthcare service use occur already before the AD diagnosis. However, little is known how the different diagnosis categories contribute to this increase in healthcare use. We investigated how the hospitalizations and specialized healthcare outpatient visits from different diagnosis categories, based on the International Classification of Diseases (ICD-10) chapters, contribute to increased specialized healthcare service use during ten-year period preceding AD diagnosis. Methods A register-based nationwide cohort of 42,934 community-dwelling persons who received clinically verified AD diagnosis in between 2008 and 2011 in Finland and 1:1 age, sex and hospital district- matched comparison cohort were included. Hospitalizations and specialized healthcare visits were categorized by the main diagnosis, according to the ICD-10 chapters. AD and dementia were separated to their own category. The number of persons with visits and stays was calculated for every 6 months, irrespective of the frequency of visits/stays individual had during that time window. Furthermore, the relative distribution of the diagnosis categories was computed. Results AD cohort was more likely to have visits and stays during the 10-year period (OR 1.19, 95% CI 1.17–1.21). The number of persons with visits and stays peaked in AD cohort from 1.5 years before the diagnosis when the differences in relative distribution of different diagnosis categories also became evident. The largest differences were observed for visits/stays with cognitive disorders, symptoms of unspecified diseases and psychiatric disorders diagnoses, and those with missing diagnosis codes in the last time window before AD diagnosis. Conclusions and implications Increased healthcare service use before AD diagnosis does not seem to arise from differences in specific diagnosis categories of ICD-10 such as diseases of the circulatory system, but from the higher frequency of visits and stays among persons with AD across diagnosis categories. Based on the relative distribution of diagnosis categories, the steep increase in healthcare service use just before and during the diagnostic process is likely due to prodromal symptoms and visits related to cognition.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Diagnostic groups of hospital stays and outpatient visits during 10 years before Alzheimer’s disease

Mäklin

Lampela

Lin

et al. 2023

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…It commonly arises from dominantly inherited mutations in amyloid precursor protein ( APP ), encoding presenilin 1 ( PSEN1 ), and encoding presenilin 2 ( PSEN2 ) (Lanoiselée et al, 2017). Sporadic AD account for the remaining AD cases and results in late‐onset AD (LOAD) that clinically manifests in individuals over the age of 65 (Rujeedawa et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Advances in nanoprobes for molecular MRI of Alzheimer's disease

Parekh,

Badachhape,

Tanifum

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Alzheimer's disease is the most common cause of dementia and a leading cause of mortality in the elderly population. Diagnosis of Alzheimer's disease has traditionally relied on evaluation of clinical symptoms for cognitive impairment with a definitive diagnosis requiring post‐mortem demonstration of neuropathology. However, advances in disease pathogenesis have revealed that patients exhibit Alzheimer's disease pathology several decades before the manifestation of clinical symptoms. Magnetic resonance imaging (MRI) plays an important role in the management of patients with Alzheimer's disease. The clinical availability of molecular MRI (mMRI) contrast agents can revolutionize the diagnosis of Alzheimer's disease. In this article, we review advances in nanoparticle contrast agents, also referred to as nanoprobes, for mMRI of Alzheimer's disease.This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease

show abstract

“…Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disease which affects more than 50 million patients and represents 60–80% of all cases of dementia [ 1 ]. The pathological feature of AD is the accumulation of extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) in the brain, leading to the loss of neurons and synapses, and consequently to cognitive impairment and dementia [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Computational Analysis of Pathogenetic Pathways in Alzheimer’s Disease and Prediction of Potential Therapeutic Drugs

et al. 2022

View full text Add to dashboard Cite

Background. Alzheimer’s disease (AD) is a chronic and progressive neurodegenerative disease which affects more than 50 million patients and represents 60–80% of all cases of dementia. Mutations in the APP gene, mostly affecting the γ-secretase site of cleavage and presenilin mutations, have been identified in inherited forms of AD. Methods. In the present study, we performed a meta-analysis of the transcriptional signatures that characterize two familial AD mutations (APPV7171F and PSEN1M146V) in order to characterize the common altered biomolecular pathways affected by these mutations. Next, an anti-signature perturbation analysis was performed using the AD meta-signature and the drug meta-signatures obtained from the L1000 database, using cosine similarity as distance metrics. Results. Overall, the meta-analysis identified 1479 differentially expressed genes (DEGs), 684 downregulated genes, and 795 upregulated genes. Additionally, we found 14 drugs with a significant anti-similarity to the AD signature, with the top five drugs being naftifine, moricizine, ketoconazole, perindopril, and fexofenadine. Conclusions. This study aimed to integrate the transcriptional profiles associated with common familial AD mutations in neurons in order to characterize the pathogenetic mechanisms involved in AD and to find more effective drugs for AD.

show abstract

The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer’s Disease

Cited by 18 publications

References 252 publications

Diagnostic groups of hospital stays and outpatient visits during 10 years before Alzheimer’s disease

Diagnostic groups of hospital stays and outpatient visits during 10 years before Alzheimer’s disease

Advances in nanoprobes for molecular MRI of Alzheimer's disease

Computational Analysis of Pathogenetic Pathways in Alzheimer’s Disease and Prediction of Potential Therapeutic Drugs

Contact Info

Product

Resources

About